In conclusion, derazantinib monotherapy demonstrated a favourable safety profile at a dose of 300 mg daily with promising anti-tumour activity in a selected patient population of iCCA with FGFR2 gene fusion following disease progression on first-line systemic chemotherapy. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.